Prevention and Management of Type 2 Diabetes and Metabolic Syndrome in the Time of COVID-19: Should We Add a Cup of Coffee? by Semiz, S. & Serdarevic, F. (Fadila)
MINI REVIEW
published: 06 October 2020
doi: 10.3389/fnut.2020.581680
Frontiers in Nutrition | www.frontiersin.org 1 October 2020 | Volume 7 | Article 581680
Edited by:
Giuseppe Grosso,
NNEdPro Global Centre for Nutrition
and Health, United Kingdom
Reviewed by:
Agnieszka Micek,
Jagiellonian University, Poland
Cristian Ricci,
University Hospital Leipzig, Germany
*Correspondence:
Sabina Semiz
sabina.semiz@ku.ac.ae;
sabinasemiz@hotmail.com
Specialty section:
This article was submitted to
Nutritional Epidemiology,
a section of the journal
Frontiers in Nutrition
Received: 09 July 2020
Accepted: 07 September 2020
Published: 06 October 2020
Citation:
Semiz S and Serdarevic F (2020)
Prevention and Management of Type
2 Diabetes and Metabolic Syndrome
in the Time of COVID-19: Should We
Add a Cup of Coffee?
Front. Nutr. 7:581680.
doi: 10.3389/fnut.2020.581680
Prevention and Management of Type
2 Diabetes and Metabolic Syndrome
in the Time of COVID-19: Should We
Add a Cup of Coffee?
Sabina Semiz 1,2* and Fadila Serdarevic 2,3
1College of Medicine and Health Sciences, Khalifa University, Abu Dhabi, United Arab Emirates, 2 Association South East
European Network for Medical Research-SOVE, Sarajevo, Bosnia and Herzegovina, 3Department of Child and Adolescent
Psychiatry, Erasmus Medical Centre Rotterdam, Rotterdam, Netherlands
Recent evidence shows that COVID-19 patients with existing metabolic disorders, such
as diabetes and metabolic syndrome, are exposed to a high risk of morbidity and
mortality. At the same time, in order to manage the pandemic, the health authorities
around the world are advising people to stay at home. This results in decreased physical
activity and an increased consumption of an unhealthy diet, which often leads to an
increase in body weight, risk for diabetes, insulin resistance, and metabolic syndrome,
and thus, paradoxically, to a high risk of morbidity and mortality due to COVID-19
complications. Here we summarize the evidence demonstrating that the promotion of
a healthy life style, including physical activity and a dietary intake of natural polyphenols
present in coffee and tea, has the potential to improve the prevention andmanagement of
insulin resistance and diabetes in the time of COVID-19 pandemic. Particularly, it would
be pertinent to evaluate further the potential positive effects of coffee beverages, rich
in natural polyphenols, as an adjuvant therapy for COVID-19, which appear not to be
studied sufficiently.
Keywords: polyphenols, coffee, COVID-19, ACE2, type 2 diabetes, obesity, insulin resistance, physical activity
INTRODUCTION
As we have just approached the 10 millionth case of the novel coronavirus disease (COVID-
19) worldwide, an increasing amount of evidence has been accumulating to indicate its poorer
prognosis in patients with diabetes and hypertension, who appear to be exposed to the greater
risk of the severe morbidity and mortality (1–3). A recent meta-analysis demonstrated that
the incidences of diabetes and hypertension were about two-fold higher, and cardio- and
cerebrovascular diseases were three-fold higher in severe/intensive care unit (ICU) cases as
compared to non-ICU severe cases (4). Similarly, another recent report showed that the triglyceride
and glucose index (TyG) was associated with an increased risk of morbidity and mortality in
COVID-19 patients, suggesting that this marker of insulin resistance could also be a valuable
marker for identifying a poor outcome of coronavirus infection (5).
Human pathogenic coronaviruses, including severe acute respiratory syndrome coronavirus
[SARSCoV] and SARSCoV-2, enter cells upon binding through angiotensin-converting enzyme
2 (ACE2), a recently characterized monocarboxypeptidase and the first ACE homolog. The ACE-2
receptor is a part of the renin-angiotensin-system (RAS), consisting of classical ACE-Ang-II-AT1R
axis and non-classical, recently discovered ACE-2-(A1-7)-Mas axis. The enzyme ACE2 generates
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additional RAS peptides, such as Angiotensin-1-7 (A1-7), which
is associated with the unique functions of this multifaceted
system (6). Interestingly, an upregulation of ACE-Ang-II-AT1R
axis leading to pro-inflammatory effects, insulin secretory defects
and increased insulin resistance was demonstrated in people with
underlying lipid and other metabolic disturbances, such as in the
case of metabolic syndrome and diabetes (2). In parallel, there is a
downregulation of ACE-2-(A1-7)-Mas axis and thus, diminished
anti-inflammatory effects and protection against pancreatitis and
insulin resistance. It is proposed that the already distraught
ACE-2-(A1-7)-Mas in diabetes/insulin resistance is additionally
strained due to the virus’s use of the ACE-2 to enter the host
cell (2).
ACE2 is expressed in the lung, intestine, kidney, blood vessels,
cardiomyocytes, immune and other cells (7–12). Since ACE2 is
expressed in the liver (13), skeletal muscle (14), and adipose tissue
(15), it is proposed that by being present in these insulin sensitive
organs, the ACE2 may have a role in regulating insulin sensitivity
and glucose homeostasis (16). ACE2 expression is reduced in
patients with Type 2 Diabetes (T2D) and kidney dysfunction
(17, 18). It was also suggested that decreased expression of ACE2
and use of RAS system antagonists in diabetes management
may contribute to poor prognosis in COVID-19 patients (19).
Furthermore, ACE2 genetic variants are reported to be associated
with T2D, hypertension, dyslipidemia, carotid arteriosclerosis
and left ventricular remodeling (20). It was suggested that
ACE2 polymorphisms may be used as novel risk markers for
the left ventricular hypertrophy (LVH) in hypertensive patients
(21) and ACE2 variation was indicated to be associated with
risk for cardiomyopathies (22). Indeed, recent COVID-19 cases
demonstrated cardiac dysfunction as a serious complication and
prognostic tool (23).
Previous studies have shown that ACE2 knockout mice had
impaired glucose tolerance or diabetes, as well as dysfunction
of endoplasmic reticulum and mitochondria in skeletal muscle
that could be improved by ACE2 activation (24). Interestingly,
Takeda et al. (16) demonstrated a beneficial role of ACE2 in T2D
management and a protective role against caloric overload, likely
via regulation of GLUT4 expression and glucose uptake (16). It
was also shown that the activation of the ACE2/(A1-7)/Mas axis
can improve hepatic insulin resistance, increase glucose uptake
and decrease glycogen synthesis in the liver (25), therefore ACE2
was suggested to be a novel drug target for treating insulin
resistance (26).
ACE2 enzyme has been also identified in pancreatic islets
and it was recommended to monitor serious COVID-19 cases
for the pancreas damage (27). A protective role of ACE2 in
the pancreas was suggested based on the recent findings of an
increased ratio of dedifferentiated beta cells in ACE2-knockout
mice under high-fat diet and consequent insulin resistance,
which was improved after the administration of A1-7 (28).
A recent review outlined several protective effects of the A1-
7 mimetics observed in animal studies, including protection
from atherogenesis, cardiovascular dysfunction, and cardiac
hypertrophy (29). It was shown that high glucose levels can
activate the ACE2/(A1-7)/Mas and APN/Ang IV/IRAP RAS
axes simultaneously with increased insulin secretion in the rat
insulinoma cell line (30). Frantz et al. (31) demonstrated that
enalapril treatment protected against the body mass increase,
normalized the islet morphology, function, and beta cell mass,
thus preserving the pancreatic beta-cell function probably by
activating the ACE2/(A1-7)/Mas receptor axis.
PHYSICAL ACTIVITY AND COVID-19
Due to the COVID-19 pandemic, a large number of people
around the world have been in self-isolation or quarantine
for several weeks or months. In addition, social activities
have been discouraged, unhealthy diets are being consumed in
higher amounts, while exercise facilities, national parks, and
playgrounds have been closed. A recent study examined adults’
physical activity during the COVID-19 imposed confinement in
Belgium, and found that most of the people participating in the
study reported to exercise less and sit more during the lockdown
(32). Another study performed in the USA showed that 48%
of obese patients exercised less, 50% increased food stockpiling
and about 60% increased stress-related eating, while 73% of
them reported increased anxiety and 84% augmented depression
since the confinement was initiated (33). A recent USA survey
indicated that about 90% of responders spent more time at
home and 22% gained 5–10 pounds, mostly due to absence of
dietary restraint, stress-stimulated eating, and reduced physical
activity imposed by COVID-19 confinement (34). Furthermore,
an Italian survey performed in April 2020 indicated that weight
gain was observed in almost 50% of the population, despite some
positive self-implemented life style modifications (35). A recent
international online survey, performed in Asian, African and
European populations, reported the negative effect of COVID-
19 home confinement on all physical activity intensity levels,
including vigorous, moderate, and walking activities, as well as
showed that daily sitting time increased from 5 to 8 h per day,
along with unhealthier food consumption and meal plan (36).
Recent studies explored the health impacts of a prolonged
reduction in physical activity and overeating under
circumstances of home confinement and found that increased
total body fat and elevated levels of inflammatory cytokines
appear to be major factors in exacerbation of insulin resistance
(1). Another unhealthy consequence of COVID-19 imposed
home confinement is the limited exposure to daily light, which
can lead to decreased levels of Vitamin D, essential to perturb
viral cellular infection by interacting with ACE2 cell entry
receptors (37). In addition to the well-established association
between vitamin D deficiency and insulin resistance and
T2D risk (38), recent publications suggest its association with
COVID-19 severity (39, 40).
MANAGEMENT OF INSULIN RESISTANCE
IN THE TIME OF COVID-19
In order to combat the undesirable changes in the lifestyle and
dietary habits adopted during the current COVID-19 pandemic,
personalized lifestyle modifications, including home exercising
and consuming healthy food, are being promoted. A recent study
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recommended regular exercise, together with a modest (20–25%)
reduction in caloric intake, for protecting cardiovascular function
(41) and inducing positive immunomodulatory effects (42).
Furthermore, exercise-induced immunomodulation might be a
key tool in improving immune responses against the SARS-CoV-
2 infection. This is in line with the well-established intervention
to increase physical activity and reduce body weight as the
first-line recommendation in preventing and treating insulin
resistance, (pre)diabetes, metabolic syndrome, and other related
disorders (43), which apparently has a high potential to diminish
risk of severe form of COVID-19.
In addition to stimulating healthy lifestyle choices, the
management of insulin resistance, pre-diabetes and T2D is
supported by pharmacological treatment, with multiple targets
for preventive and treatment interventions. As described earlier,
the key components in SARSCoV-2 viral entry are ACE2 receptor
for cell entrance and the serine protease TMPRSS2 for the
proteolytic cleavage of viral spike (S) protein (44). Recently,
it was shown that T2D patients had increased plasma total
protease and serine protease activities (45). Interestingly, plasma
serine protease activity was positively associated with levels
of hemoglobin A1c (HbA1c), body mass index (BMI) and
homeostasis model assessment-insulin resistance (HOMA-IR)
index, thus, supporting the potential role of serine protease in
development of T2D and offering novel drug targets for T2D
management (45). Furthermore, it was proposed that the already
available recombinant ACE2 may be employed for treating
COVID-19 (46).
Evidence has been accumulating to demonstrate the beneficial
effects of metformin, the first-choice oral anti-diabetic drug, in
treating several other aging-related diseases, including obesity,
pre-diabetes, metabolic syndrome, cardiovascular disease, non-
alcoholic fatty liver disease (NAFLD), cancer, cognitive decline
(47), as well as immunomodulatory, and other defects (48–50).
Interestingly, a recent study performed in the Tongji Hospital of
Wuhan in China showed that diabetes treatment with metformin
was associated with decreased mortality as compared to diabetics
not treated with this medication (51). Furthermore, it was
suggested that metformin may have an inhibitory effect on
the virus, through increased insulin sensitivity (52). Another
study performed in the patients older than 65 years of age,
who were hospitalized with pneumonia and with a history
of diabetes, found that the preceding metformin treatment
was associated with a markedly lower death rate in those
patients (53). In line with this, it was recently suggested to
use metformin as an adjuvant therapy in older, obese, and
diabetic patients with COVID-19, who would benefit from this
treatment through the reduction of weight, pneumonia, and
protrombotic events, partially through the metformin’s ability
to prevent inflammation and decrease high circulating levels of
cytokines, such as interleukin-6 (IL-6) (54). However, another
recent paper cautioned that in patients with severe forms of
COVID-19, who are exposed to the risks of lactic acidosis and
ketoacidosis, metformin and sodium-glucose co-transporter-2
(SGLT2) inhibitors should be discontinued (55).
Furthermore, a recent study showed that pioglitazone
treatment significantly increased the serum levels of ACE2,
angiotensin-(1-7) and the hepatic ACE2 expression (56).
Pioglitazone belongs to the class of oral antidiabetic drugs,
thiazolidinediones (TZD), which were introduced about 10 years
ago and widely used to treat insulin resistance and T2D until
recently, when discontinued due to increased cardiovascular
risk associated with rosiglitazone administration (57). However,
TZDs use for the treatment of other diseases has been revaluated
in regards to their anti-inflammatory properties (58), including
their potential use in treating COVID-19.
BENEFICIAL EFFECTS OF DIETARY
POLYPHENOLS IN COVID-19
MANAGEMENT
A growing evidence from epidemiological studies demonstrated
that dietary polyphenols might be used to treat and prevent
T2D obesity, and insulin resistance (59). Polyphenols from the
grape seed, olive oil, tea, coffee, propolis, cocoa, and chocolate
have been shown to have anti-diabetic effects through reducing
insulin resistance, glucose and HbA1c levels (60). Resveratrol
is a polyphenol and potent antioxidant found in grape, which
demonstrated anti-inflammatory and antiviral activity against
several viruses (61). A recent meta-analysis indicated that
resveratrol may improve cardiometabolic status and alleviate
certain risk factors for cardiovascular disease, including insulin
resistance and elevated cholesterol levels (62). Furthermore,
previous studies demonstrated that resveratrol can deactivate
the renin-angiotensin system (63, 64) and have a protective role
by upregulating ACE2 (65). Interestingly, as the recent report
suggested, resveratrol can be a promising anti-COVID-19 drug
candidate, likely acting through interference with the viral spike
protein function (66). This is in line with the results from
previous studies, which have shown that resveratrol inhibited
the Middle East Respiratory Syndrome coronavirus (MERS-
CoV), extended cellular survival after virus infection (67), and
demonstrated antiviral activity against other viruses (68).
In addition to resveratrol, other polyphenols also
demonstrated a beneficial effect in COVID-19 management.
Recent reports summarized diverse natural compounds, with the
majority being classified as polyphenols, which demonstrated
their potential to inhibit coronavirus in humans (69, 70), as
well as other viruses (71–74). The potential effects of curcumin,
a natural polyphenolic compound, include inhibition of the
entry of virus, its encapsulation, and activity of viral protease,
suggesting its therapeutic potential in treating SARS-CoV-2 (75).
The major components of tea polyphenols, such as theaflavins,
showed anti-HIV effect (76), while catechins demonstrated
anti-diabetic (77) and hypocholesterolemic activities (78).
Furthermore, tea extracts showed antioxidant activity (79) and
beneficial effects on protein oxidation- and glycation-associated
diseases (80). Importantly, the tea components also showed
antiviral activity against the influenza B, H1N1 and H3N2
influenza viruses, most likely through the inhibiting of virus
adsorption and replication (81). It has been shown that green tea
extract can be used as natural disinfectant (82, 83). In addition
to their virucidal activity against a spectra of viruses, including
influenza virus, herpes simplex virus, vaccinia virus, coxsackie
virus, poliovirus-1, and human rotavirus, theaflavins also
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demonstrated the ability to alleviate bovine rotavirus and bovine
coronavirus infections (84). The beneficial effects of green tea,
black tea, and oolong tea have been well-known for many years
and a recent study demonstrated that oolonghomobisflavan-A
is a potential bioactive molecule responsible for beneficial tea
effects, most likely acting through the inhibition of the main
protease of SARS-CoV-2 (85). Three polyphenols, including
epicatechingallate, epigallocatechin gallate, and gallocatechin-
3-gallate, from green tea were selected as promising drug
candidates to treat COVID-19 due to their strong interaction
with one or both residues in Cys145–His41 catalytic dyad of the
main protease of SARS-COV-2 (86).
COFFEE IN THE TIME OF COVID-19
In addition to tea, coffee is another commonly consumed
beverage in the world, which appears to increase insulin
sensitivity and glucose uptake in skeletal muscle. A recent
report identified for the first time that the phytochemicals
from coffee and cocoa affect the phosphorylation of the
insulin receptor signaling pathway and stimulated GLUT-4
translocation, increasing intracellular glucose utilization (87). In
line with this, a systematic review of clinical trials analyzing the
effects of coffee consumption on glucose metabolism, indicated
an improvement of insulin response and glucose metabolism
in long-term studies (88). Previous studies have shown that in
animal models chronic caffeine intake prevented and reversed
insulin resistance induced by aging and hypercaloric diets (89).
Recently, coffee consumption by high-risk diabetic individuals
was positively associated with pancreatic beta cell function,
so they had lower fasting glucose levels, higher insulin levels
and higher insulin secretion indexes upon coffee intake (90).
Furthermore, a recent systematic review and meta-analysis
showed that green coffee supplementation significantly decreased
levels of fasting glucose, insulin, and triglyceride, and improved
HDL levels, thus positively affecting the cardiometabolic risk
factors (91). Nikpayam et al. (92) also demonstrated a similar
effect of green coffee extract on fasting glucose levels andHOMA-
IR. Chlorogenic acid, the most abundant biologically active
dietary polyphenol in coffee, has been suggested to be responsible
for alleviating several cardiometabolic risk factors (93). These
beneficial anti-diabetic, anti-obesity, anti-inflammatory and
anti-carcinogenic effects seem to be further accompanied by
immunomodulatory effects and changes in gut microbiota (94).
Interestingly, derivatives of chlorogenic acid, including 3,4-
O-dicaffeoyl-1,5-γ-quinide, showed in vitro a potent antiviral
effect against respiratory syncytial virus, probably acting on
an intracellular post-entry replication step (95). Thus, these
data suggest that drinking coffee may represent an additional,
beneficial strategy in treating viral disease. However, based on our
knowledge, it appears that these studies have not been performed
in vivo yet.
In line with described antidiabetic effects of tea polyphenols,
a recent study performed in about 130.000 Korean adults found
that increased coffee consumption (more than four cups per day)
was associated with a lower prevalence of metabolic syndrome,
as compared to non-coffee consumers (96). Another recent
study also performed in Korean populations demonstrated that
moderate to high coffee intake is inversely associated with the
metabolic syndrome (97). Similarly, positive effects of coffee
consumption were also demonstrated in Polish population, in
which coffee intake was inversely associated with a risk of
metabolic syndrome (98–100) and T2D (101). Furthermore,
recent studies performed in Japan and Brazil, showed that
decaffeinated coffee consumption improved insulin sensitivity in
healthy men (102, 103). Another study from Sweden showed
an advantage of filtered over boiled coffee when it comes to
the protective role of coffee on T2D development (104). It
was suggested that long-term consumption of coffee beverages
is associated with a lower risk of T2D, probably via multiple
mechanisms, including effects on glucose homeostasis, oxidative
stress and inflammation (105). Therefore, it would be pertinent
to study the potential effects of coffee intake in management and
prevention of viral disease, including COVID-19, which seem
not be studied in vivo yet. At the same time, it would also be
important to evaluate further the potential detrimental effects of
coffee intake, for example, its effects on sleep quality (106) and
endothelial vascular function (107, 108), which may also affect
COVID-19 outcome.
CONCLUSION
Thus, apart from existing general preventive and safety measures
recommended to the general public, maintaining physical activity
and choosing a diet and beverages rich in polyphenols, such as
tea and coffee, might be important interventions in achieving an
optimal public health and offering more efficient and enjoyable
way to deal with the COVID-19 pandemic. Particularly, the
potential positive effects of coffee consumption as an adjuvant
therapy for preventing and managing COVID-19 seem not to be
elucidated enough, so further studies are warranted to confirm
these beneficial properties.
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